Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Idorsia’s Quviviq wins FDA approval for insomnia

By Brian Buntz | January 10, 2022

idorsiaIdorsia Ltd (SIX:IDIA) has received FDA approval for 25- and 50-mg doses of Quviviq (daridorexant), a dual orexin receptor antagonist.

Quiviviq is the first compound in its pipeline to win FDA approval.

The drug works differently from traditional benzodiazepines, which modulate neuronal activity. By contrast, daridorexant inhibits the binding of orexins to reduce excessive wakefulness.

FDA approved the drug based on Phase 3 data that showed that the drug offered faster sleep onset and better sleep maintenance over placebo. In the study, the drug was also associated with longer total sleep time, which enrolled 1,854 adults with insomnia in 18 countries.

“After more than 20 years of research and a progressive understanding of the role of orexin in sleep-wake balance and of the potential of orexin receptor antagonism, we designed daridorexant to help address several issues people with insomnia face,” said Dr. Martine Clozel, chief scientific officer. “Daridorexant properties include a potent inhibition of both orexin receptors, a rapid absorption for sleep onset, and a pharmacokinetic profile such that around 80% of daridorexant has been eliminated after a night of sleep to help minimize residual effects.”

FDA has recommended that the Drug Enforcement Administration (DEA) classify Quviviq as a controlled substance. Allschwil, Switzerland–based Idorsia anticipates that the drug will hit the market in the summer.

Roughly one-third to half of adults have intermittent insomnia symptoms, while about 10–15% have chronic insomnia, according to the Cleveland Clinic.

Idorsia saw IDIA shares tick down 5.54% to $20.45 after announcing the FDA approval.

The company was incorporated in 2017.

Idorsia has several other products in Phase 3 trials.

The company also has a collaboration agreement with Janssen, which it announced in 2017.


Filed Under: clinical trials, Drug Discovery, Psychiatric/psychotropic drugs
Tagged With: daridorexant, FDA, idorsia, insomnia, Quviviq
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

psychedelic medicine discussed at SXSW
5 headwinds and 5 tailwinds for psychedelic medicine
lab microscope
Accelerating R&D with FAIR data
Kallyope
Kallyope’s focus on the gut-brain axis yields a diverse portfolio
Axcella
Axcella touts positive results from Phase 2a long COVID study

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Medtech100 Index
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50